SEATTLE, Sept. 19, 2025 /PRNewswire/ — HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared […]
HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ — HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine […]
Self-amplifying RNA vaccine, delivered by cationic nanocarrier (LION™) elicits neutralizing antibody responses in mice and nonhuman primates and protects mice from enterovirus D68 (EV-D68) respiratory infection and resulting disease in mice. Findings published in the […]
